Introduction
Any young ophthalmologist wishing to explore the scientific basis of ophthalmic disease could not adopt a better role model than William Bowman, who arguably was our most remarkable and pre-eminent clinician-scientist. In 1832, at the early age of 16 years, Bowman served as apprentice to the Birmingham surgeon Hodgson, with whom he developed his exceptional observational and recording skills. Later, as an anatomy demonstrator and medical student at King's College, London, he demonstrated his huge capacity for assembling, cataloguing and organising data, leading to the compilation of a comprehensive work on the anatomy and physiology of the body, a standard text at the time. 1 •2
Before long Bowman's insatiable appetite for discovery, coupled with the serendipitous acquisition of a new compound microscope, led him to explore the microanatomy of numerous human and vertebrate tissues and organs and indulge his passion for the meticulous and exact recording of his findings, often in breathtaking detail, given his tools at the time. He made many clinico-pathological correlations in diverse disease processes and elegantly documented, for the first time, structures in the eye and kidney which bear his name to this day.
Bowman's ordered and disciplined approach to the analysis and documentation of his anatomical and pathological discoveries was matched only by a raft of innovations relating to the preservation and fixation of histological specimens which allowed him to survey the delicate and intricate tissues of the eye in unprecedented detail. He used the ' glycational' properties of syrup to stabilise and fixate the friable and unwieldy retina long before standard cross-linking techniques evolved and exploited agitational micro-dissection methods to separate the retinal microvascular from neural tissue more than a century in advance of trypsin digestion methods?
Eye (1999) 13, 497-523 © 1999 Royal College of Ophthalmologists DESMOND B. ARCHER Bowman made no direct contribution to the understanding of the pathology or pathogenesis of diabetes mellitus as the link between pancreatic islet cell loss and glycosuria was only established by Minkowski in 1889, some 50 years after Bowman's principal discoveries? Nevertheless, Bowman's incisive anatomical studies on three of the prime targets for diabetes, i.e. basement membranes, muscle cells and the renal glomerulus, provided a firm histological platform for future pathological studies.
It has been known for at least 120 years that diabetes mellitus has a deleterious effect on the retinal circulation, and reports dating to the last century clearly depict the characteristic and often inexorable retinopathy that afflicted patients with severe, uncontrolled and long standing disease. 4 •5 The discovery of insulin in 1923 dramatically improved the survival of insulin-dependent diabetics but increased the length of time the retinal vasculature was exposed to conditions of variable glycaemia, and diabetic retinopathy was ultimately found to affect most insulin-dependent and non insulin-dependent diabetics who survived the condition for 20 years or 10nger.6•7 Despite advances in medical and surgical management, diabetic retinopathy remains the commonest cause of registrable blindness in young and working adults in the United Kingdom and most industrialised countries. 8 Because of its visibility and ready access to photography the retinal vasculature has been the most scrutinised microcirculation in the body and in the 1960s angiographic techniques were developed which could resolve capillaries measuring only 5-10 /Lm in diameter. Since then diabetic retinopathy has been documented in exquisite detail, revealing characteristic vessel calibre changes, microaneurysms, perfusion defects and intra-and preretinal neovascularisation in the affected microvasculature. Fluorescein angiography has provided a sensitive measurement of vascular competence and in parallel with other ingenious techniques such as laser Doppler interferometry and blue entopic field measurements, demonstrated a range of haemodynamic alterations during the course of the disease process.
In vivo structural and functional analyses of the human diabetic retinal microvasculature were paralleled by histopathological investigations which exploited the regular architecture of the retinal vessels and their resistance to trypsin digestion. Basement membrane thickening and pericyte loss were established as the histological hallmarks of early diabetic retinopathy and vascular occlusion, with varying degrees of channel repair and extraretinal vasoproliferation, was recognised as the key feature of more advanced retinopathy. Animal models of diabetic retinopathy, although not fully reproducing the human vasculopathy, helped unravel some of the early dynamic and histopathological changes induced by a hyperglycaemic microenvironment. Cell culture studies facilitated analysis of retinal microvascular pericytes and endothelial cells in isolation and in co-cultures, adding to our knowledge of the unique molecular and biochemical properties of these cells and their responses to high glucose concentrations. The application of ultrastructural, biochemical and molecular biological investigative methods to the retinal circulation have also clarified how vascular and paravascular cell processes alter in diabetes. Such studies
have highlighted conditions under which such cells can become progressively dysfunctional and suggested strategic points in the disease process where corrective or supportive therapies might be instituted.
There have been few therapeutic innovations to prevent or significantly ameliorate diabetic retinopathy, and at present emphasis is on achieving near euglycaemia and avoiding or modulating known risk factors, such as smoking, uncontrolled hypertension, hyperlipidaemia and anaemia. 9 , l O Treatment for established and sight-threatening diabetic retinopathy is largely by laser photocoagulation. This technique has proven value in certain forms of diabetic retinopathy, but is inherently destructive and has its own retinue of complications, particularly loss of colour vision, contrast sensitivity and visual field. Vitreous haemorrhage and fibrovascular membranes which threaten the macula can be removed by vitrectomy procedures and serviceable vision salvaged; however, many such patients already have ischaemic retinae where the disease process has largely run its natural course and visual recovery may be disappointing.
It is now clear that any treatment to preserve full vision in diabetes must be instituted before capillary instability, incompetence and closure occur. This requires a more sophisticated understanding of the inner blood-retinal barrier and the response of its component cells to sustained hyperglycaemia, This paper outlines some of the molecular, biochemical, morphological and physiological abnormalities which occur in retinal vascular cells during diabetes and analyses how dysfunction and death might be prevented or conversely, how their survival and normal function may be perpetuated.
Diabetic retinopathy: the microvascular substrate
The retinal vasculature is unique in that its major vessels are mostly arterioles (without an internal elastic lamina), which lack an autonomic nerve supply and function in the presence of a high tissue pressure, i.e. the intraocular pressure. The capillary is the key circulatory interface within the retinal neuropile and is composed of a continuous endothelium supported by a thick basement membrane and surrounded by pericytes which have contractile and vasoregulative properties. The capillary unit is encased within neuroglia which also contribute to microvascular function and survival (Fig. 1) .
Individual vascular endothelial cells are joined by occluding junctional complexes (zonulae occludens, ZO) and constitute the inner blood-retinal barrier, which is structurally and functionally analogous to the blood-brain barrier. The barrier properties of the retinal vascular endothelium are influenced by the surrounding neuroglia which secrete agents to maintain tight junction formation and their specialised ZO-l protein content. ll , l 2
The vascular endothelial cell is central to the maintenance of normal blood flow, local rheology and the preservation of metabolic homeostasis in the neighbouring neuropile. Endothelial cells communicate directly with pericytes and smooth muscle cells via gap junctions 1 3, 1 4 and actively regulate capillary and arteriolar tone and calibre by elaborating vasodilators (nitric oxide (NO), adenosine, prostanoids) and vasoconstrictors (endothelin-1, angiotensin II) in response to local metabolic needs (Fig. 2) . Some recent studies suggest that NO synthase (NOS)-containing neurones may have a vasoregulatory role in the retina; however, as noted, the retinal vasculature itself is devoid of an extrinsic innervation and its function is largely maintained by the autocrine and paracrine activity of its component cells.
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Although the retinal capillary unit is largely autonomous in terms of local control of rheology and tissue metabolism, blood flow into the capillary bed is determined by the state of contraction of the upstream pre-capillary arteriole whose smooth muscle cells are highly sensitive to endothelium-generated vasodilators and vasoconstrictors. Failure of the pre-capillary arteriole to regulate blood flow to the capillaries can have calamitous consequences for downstream haemodynamics, as occurs in some diabetics, and it is not surprising that microaneurysm formation predominates on the arterial side of the circulation where smooth muscle cells have been IOSt. 1 6 Similarly failure and obstruction of the post-capillary venule can influence capillary hydrostatic pressures, blood flow, oxygen saturation and microvascular competence.
The vascular endothelium determines the composition of its basement membrane by secreting components of the extracellular matrix (e.g. laminin, fibronectin, entactin, collagen IV 1 4) and remodelling it with degradative enzymes (e.g. collagenases and less specific matrix metalloproteases (MMPs). Basement membrane components are also secreted by pericytes, smooth muscle cells and neuroglia and the composite vascular matrix immobilises various heparin-binding paracrine growth factors (e.g. vascular endothelial growth factor (VEGF), basic fibroblastic growth factor (bFGF)) in addition to providing structural support P Local rheology is also influenced by the vascular endothelium, which has the potential to generate both pro-coagulant and anti-coagulant factors, and inhibit platelet adhesion by producing prostacyclin, and the platelet inhibiting factor NO. Fibrinolysis may also be endothelium-modified by the generation of either tissue like plasminogen activator (TP A) or its inhibitor (TPAI). 18 The vascular endothelium controls transcellular migration of blood-borne leucocytes to the neuropile by the regulation of adhesion molecules such as the selectins and ICAM-l/VCAM-l in response to inflammatory stimuli. It is notable that P-selectin, an adhesion molecule important to early inflammatory cell recruitment, is co expressed with the pro-coagulant von Willebrand factor which is contained within Weibel-Palade bodies in the vascular endothelium. 19 In terms of survival, retinal endothelial cells are resilient cells with a very low natural tumover?O They can readily replicate to repair localised damage and re endothelialise defunct capillaries to a limited extent. In conditions of chronic hypoxia or ischaemia retinal vascular endothelial cells can proliferate rapidly to form sizeable preretinal neovascular membranes.
Retinal pericytes surround the endothelial tube encased within the thick basement membrane (Fig. 1 Risk factors for the development of microangiopathy in diabetic patients include hyperglycaemia, hyperinsulinaemia, hypoinsulinaemia, hyperlipidaemia, increased by-products of insulin secretion (pro-insulin, C peptides)/8 hypertension and less well defined genetic and environmental factors. Nevertheless, despite such a range of adverse and aphysiological factors, hyperglycaemia is unique to diabetes and the dominant force for change in terms of cell dysfunction and development of diabetic complications?3-35
Metabolic and biochemical accommodations
Homeostatic mechanisms
Regulated glucose entry
As glucose is the principal source of energy for the cell it is not surprising that its entry into the vascular endothelial cell or pericyte is facilitated by specific glucose transporter proteins (GLUT I and GLUT III) which bridge the plasma membrane of both cell types. [36] [37] [38] [39] In hyperglycaemia or hypoglycaemia these transporters can be down-regulated or up-regulated respectively to maintain constancy of intracellular glucose concentration; however, despite such limiting gateways, high concentrations of extracellular glucose in diabetes are translated to an overload of intracellular glucose sufficient to saturate some metabolic pathways (glycolysis and the tricarboxylic acid cycle), activate or exaggerate others (e.g. the polyol pathway) or attenuate others (e.g. the pentose phosphate shunt) (Fig. 3) . Insulin receptors are also present in retinal vascular cells; however, the role of insulin in glucose entry into these cells is probably less important than in other cell types. Insulin receptor binding in the retinal vasculature may have other important roles such as vasoregulation, cell survival and/or growth promotion.4o
Glycogen storage
Intracellular glucose can be stored as glycogen in some retinal cells, presumably in anticipation of high metabolic demand or oxidative needs. An example is rod photoreceptor metabolism, where increased oxygen consumption and glucose utilisation occur with dark adaptation. 41 In diabetic animals gross and possibly pathological accumulations of glycogen have been described in retinal amacrine, bipolar and glial cells which reflect sustained supra-normal intraretinal glucose concentrations. 42 Retinal vascular cells also contain scattered glycogen granules, but even in diabetes abnormal deposits are not observed.
Re-routing of gratuitous intracellular glucose
High intake of glucose into the retinal vascular cells rapidly saturates the usual glycolytic pathways and excess hexose sugars may be diverted into other biochemical pathways which are ordinarily little used or redundant. The conversion of excess cytosolic glucose to glycogen probably contributes little to cellular euglycaemia and excess glucose is typically routed through non-glycolytic pathways. A detailed description of all the various biochemical processes involved in the intracellular metabolism of glucose is beyond the scope of this work; however, during sustained hyperglycaemia certain changes occur in key biochemical processes which have implications for the function and survival of retinal vascular cells and, furthermore, may be amenable to therapeutic manipulation, and these will be considered (Fig. 3 ).43
Hyperglycaemia: intracellular biochemical perturbations
Polyol pathway and pseudohypoxia
Increased flux of glucose through the polyol pathway subsequent to hyperglycaemia results, firstly, in reduction of glucose to sorbitol by aldose reductase (coupled to oxidation of NADPH to NADP+), and secondly the oxidation of sorbitol to fructose by sorbitol dehydrogenase (linked to reduction of NAD+ to NADH). 43 The enhanced oxidation of sorbitol to fructose results in an increased cytoplasmic ratio of free NADH:NAD+. This NADH:NAD+ imbalance occurs independently of tissue oxygenation but is closely related to similar events in hypoxic tissues where there is impaired oxidation of NADH to NAD+. Williamson et al.44 describe this polyol-pathway-associated increase in the rate of reduction of NAD+ to NADH with resultant rise in NADH/NAD+ ratio in vascular tissues exposed to hyperglycaemia as pseudohypoxia, because oxygen levels remain normal. Pseudohypoxia is associated with cellular imbalances in lipid metabolism, reactive oxygen species production, protein kinase C activation and NO production, while in tissues this translates to increased blood flow, vascular hyperpermeability and abnormal growth factor expression. 45, 46 Theoretically an increase in NADH:NAD+ mimics an altered lactate-pyruvate ratio and signals the need for more oxygen and triggers the release of vasodilator prostaglandins and NO which increase blood flow. It is argued that this enhanced blood flow is independent of tissue oxygenation and less affected by increased oxygen delivery or vasoactive stimuli and would theoretically account for the persistent vasodilatation characteristic of early diabetes. In this respect it is Significant that aldose reductase inhibitors (ARls) prevent increased blood flow in acutely hyperglycaemic and diabetic rats.
Whether the hyperdynamic retinal vascular changes in human diabetes can be attributed to pseudohypoxia is not known; however, clinical trials of ARls have thus far shown no convincing effect in preventing the retinal vascular complications of diabetic subjects.47 Despite effective reduction in tissue sorbitol levels, ARls have also been ineffective in preventing non-proliferative (background) retinopathy in galactosaemic or diabetic dogs. 48 Na+ /K+-ATPase Na+ /K+-ATPase is a ubiquitous enzyme that is an integral part of the transmembrane sodium pump involved in the maintenance of cell homeostasis and regulation of many cell functions, including contractility, growth and differentiation.49�51 Na+ /K+-ATPase is altered in the neural and vascular tissues of diabetic animals and in retinal vascular cells cultured in high glucose. Reduced enzyme activity in diabetic tissues has been linked to elevation in sorbitol levels and reduced intracellular myo_inosito1.43,52,53 Na + /K+ -ATPases are important modulators of extracellular hydration and nerve conduction velocity and it has also been postulated that altered Na + /K+ -ATPase activity in hyperglycaemia may impair retinal pigment epithelial cell activity and impede dehydration of the outer retina in diabetics. ARIs prevent a decrease in Na + /K+ -ATPase activity in cultured retinal capillary endothelial cells and neurones which have been exposed to high glucose in vitro. Animal studies confirm that ARIs can prevent impaired conduction velocity in motor neurone deficiency in galactosaemic and diabetic dogs;54 however, clinical investigations have not convincingly shown that ARIs are effective against diabetic neuropathy. 55
Protein kinase C activation
Overactivity of the sorbitol pathway tends to deplete intracellular NADPH levels, reduce the cytosolic anti oxidant glutathione and thereby enhance oxidant effects. The resultant alteration in redox state may also affect NO and prostaglandin synthesis and alter the activity of protein kinase C (PKC). There are a range of PKC isoforms, many of which have important roles in intracellular signal transduction for hormones and cytokines.56 Hyperglycaemia leads to de novo synthesis of diacylglycerol (DAG) in the diabetic retinal vascular endothelium which leads directly to activation of PKC, particularly the ex and J3II isoforms.57 In diabetic animals it has been shown that PKC activation can affect vascular permeability, basement membrane synthesis, vessel contractility, blood flow (via modulation of vasoactive agents) and coagulation, as well as modulating the actions of growth factors and influencing cell growth, motility and differentiation.56,58,5 9 Abnormal PKC activation is not prevented by ARIs and probably not attributable to changes in the sorbitol pathway, Because of the immediate relevance of PKC-J3II isoforms to vascular cell dysfunction in diabetes, agents have been developed to inhibit PKC-J3II activity, Recent studies using the experimental drug L Y333531 suggest that PKC J3II activation can be curtailed and abnormal retinal haemodynamics forestalled in diabetic animals.60,61
Pathophysiological mechanisms and processes

Oxidation
The lipid-rich retinal tissues are unusually exposed to oxidative processes as the profuse choroidal and retinal circulations create an oxygen-rich milieu. Moreover, the abundant mitochondria populating the cellular and metabolically active neuropile may leak reactive oxygen species (ROS) while some ultraviolet wavelengths that irradiate the retina further exaggerate the oxidative load. Hyperglycaemia also induces or exaggerates potentially damaging biochemical processes such as glycation/ glycoxidation, polyol pathway recruitment (pseudohypoxia) and glucose auto-oxidation, all of which contribute to oxidative stress of the retina and its circulation (Fig. 4A) . 44, 62 The generation of ROS such as superoxide anion (0 2 -), hydroxyl radical (.OH) and hydrogen peroxide (H 2 0 2 ) can cause peroxidation of membrane lipids and destabilisation of cells, up-regulation of endothelial adhesion molecules and disruption of vasodilatory responses of the retinal circulation, 63 The susceptibility of the retina to oxidative stress represents a balance between pro-and anti-oxidant factors, Levels of anti-oxidants may be diminished by hyperglycaemia and retinal glutathione concentrations may be reduced in advance of structural changes in retinal vascular cells.64,65 Sharpe et al.66 suggest that retinal pericytes are less susceptible to lipid peroxidation than aortic smooth muscle cells in high glucose medium, even though glutathione levels are reduced in both cell types. Interestingly it has been suggested that there is not a generalised 'oxidative stress' in diabetes, as in one study some of the products of oxidative damage did not alter between diabetic and non-diabetic patients, probably as a result of up-regUlation of endogenous anti oxidant and free radical scavenger molecules,67 
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Non-enzymatic glycation
High concentrations of glucose in cells and extracellular spaces accelerate the spontaneous formation of glucose adducts to proteins and other amine containing molecules through the Maillard reaction. Early stages of non-enzymatic glycation products are freely reversible and can lead to ' Amadori products', an example of which is HbA l e However, with time these intermediates convert to irreverSibly modified cross-linked condensation products named 'advanced glycation endproducts' (AGEs) (Fig. 5) .
Traditionally, AGEs form on long-lived proteins such as collagens and lens crystallins where their concentration strongly correlates with the degree of glycaemic control and ageing. More recently AGEs have been quantified in serum where they may be detected on shorter half-life proteins such as haemoglobin, albumin and plasma lipoproteins and at elevated levels in diabetics. 7 2 More recently there has been an emphasis on the role of glycoxidation products which form via glycation and associated oxidation reactions with proteins.73 Also, there has been significant recognition of the rapid formation of AGEs through the action of strongly glycating reactive intermediates such as 3-deoxyglucosone and methylglyoxal which can form AGE adducts in days rather than months as with the relatively 'weak' glycating glucose. Many cells are imbued with receptors for AGEs, including retinal vascular endothelial cells and pericytes, and under normal circumstances established scavenging mechanisms eventually eliminate them from the body.
AGEs can modify retinal vascular function in a variety of ways. Glycation of plasma proteins can induce a pro coagulant state and alter blood viscosity and tissue oxygenation. The complexing of glucose to basement membrane collagen alters its thickness (reduced degradability), antigenicity, permeability, heparin sulphate proteoglycan composition, compliance and perhaps interactions with heparin-binding growth factors such as VEGF and b-FGF. Furthermore, exposure of vascular cells to AGEs causes an up-regulation of basement membrane components. Glycated basement membrane components, collagen IV, laminin, vitronectin, etc., are also resistant to remodelling by vascular endothelial cell proteases74-76 and glycated matrix may influence recognition and binding of surface receptors which may affect endothelial cell migration and proliferation. 77 Many cell types express AGE receptors and act as important AGE scavengers, removing senescent, modified molecules from the circulation and tissues. Also AGE binding to their receptors can modulate many important cell responses such as increased secretion of cytokines (TNFex, IL-l) and growth factors and up regulation of ECM gene expression.78 While fibroblasts, macrophages and leucocytes express AGE receptors, it is significant that the vascular endothelium possesses distinct AGE receptors which are regulated by AGE exposure and induce AGE-mediated vascular responses? 9
Less is known about the intracellular effects of AGEs on the retinal vasculature, although pericytes and vascular endothelial cells express AGE receptors80 which differ in their response to AGE ligands. AGE modified proteins can induce changes that promote matrix over production, focal thrombosis and vasoconstriction in the retinal vasculature?7 Cross-linking of primary amine groups of nucleic acids have major consequences for vascular cells and some studies show that single-strand DNA breaks and impaired DNA repair can occur on exposure of human vascular endothelial cells in vitro to high glucose levels. 81 It is also known that AGEs impair both activity of NO and expression of endothelial nitric oxide synthase (eNOS) by vascular endothelial cells82. 83 and may contribute to the failure of autoregulatory control in diabetic retinal vasculature.
It has recently been shown that certain components of cigarette smoke can react with plasma components and extracellular matrix to form covalent adducts with many of the properties of AGEs. 84 Smokers have been shown to have higher levels of glycated lens proteins and more AGE immunoreactivity in coronary arteries than non smokers,85 and these findings are consistent with the knowledge that smoking is a risk factor for proteinuria and loss of vision in diabetics,86 although most studies thus far have failed to show a definite connection between smoking and progression of diabetic retinopathy.87
Osmotic imbalance
Aphysiological changes in cellular and extracellular hydration are a feature of diabetes inspired by rapid changes in blood glucose. High accumulations of intracellular sorbitol can induce pathological changes in lens fibres; however, concentrations in retinal vascular cells have not been shown to be sufficient to induce osmotic gradients capable of disrupting cell architecture or function.
Hypoxia
In view of the profuse and autoregulated retinal circulation, hypoxia is probably not a significant factor in inducing the early vascular cellular changes in diabetes; however, Linsenmeier88 using oxygen microelectrodes has found evidence that retinal hypoxia can occur in diabetic cats concomitant with endothelial cell death and macrophage/leucocyte plugging of capillaries, but before there is evidence of capillary fallout. In states of hypoxia the retina is known to respond by increasing expression of VEGF,89 probably mediated by adenosine A 2 receptor activation.9o Upstream to this, there is activation of the hypoxia-regulated transcription factor hypoxia-inducible factor lex (HIF-lex) which binds to a hypoxic response element leading to increased transcription of VEGF. While this is mostly recognised in tumours and in vitro systems it has also been demonstrated in the hypoxic retina. 91 In advanced ischaemic diabetic retinopathy hypoxia almost certainly contributes to increased expression of angiogenic growth factors such as VEGF which ultimately leads to neovascularisation.89.92 Hypoxia may also influence the viability of ganglion cells in the diabetic retina by increasing glutamate release and inducing excito-toxicity changes in cells, due to uncensored Ca2+ influx, although it has been suggested that retinal ganglion cells increase expression of the 72 kDa heat shock protein which confers some tolerance to hypoxia and excitotoxicity.93
Inflammation
Certain hyperglycaemia-linked metabolic processes generate mediators of inflammation (prostaglandins, etc.) and AGEs can induce pro-inflammatory cytokines and adhesion molecules from macrophages and vascular endothelial cells (Fig. 6 ). Various adhesion molecules for inflammatory cells may also be expressed in early diabetes and some studies have shown that activated and adherent leucocytes become entrapped in capillaries and cause occlusion in early experimental diabetes. 94 -97 Inflammatory cells may also accumulate in microaneurysms and monocytes/macrophages are sometimes associated with intra-and preretinal neovascularisation, where presumably they generate angiogenic growth factors. However, in early clinical diabetes inflammation is not a biomicroscopical feature and where cell loss does occur it is probably by a process of apoptosis which does not excite a significant or identifiable inflammatory response.
Pro-coagulative state
The coagulative properties of the blood may be affected in early diabetes as evidenced by increased platelet activation, aggregation and eicosanoid production, and in later ischaemic disease the altered balance between coagulation and fibrinolysiS leads to vascular instability and occlusion (Fig. 7) .18 . 98 Hyperglycaemia may perturb the coagulation cascade by increased oxidative stress, glycation (which may increase tissue factor activityf8 and impairment of heparin sulphate proteoglycan synthesis. Polymorphonuclear leucocytes may also be less deformable in diabetes99 and are more adherent to the vascular endothelium, thereby increasing the likelihood of occlusion of small capillaries. The vascular endothelium can alter local rheological conditions by the elaboration of pro-and anti-clotting factors as illustrated by a significant increase in Weibel-Palade bodies containing von Willebrand factor in diabetic retinal vessels (Fig. 7) .100 Intraluminal thrombin and fibrin fragments are found in advanced ischaemic retinopathy and may act as strong stimulators of vascular endothelial cell growth and important instigators of capillary re endothelialisation and angiogenesis. 18 It is not known to what extent clotting or rheological abnormalities contribute to the development of diabetic retinopathy or at what point in the disease process their effect is crucial to circulatory failure. Most evidence suggests that in early diabetic retinopathy rheological changes contribute to circulatory stasis, whilst in late retinopathy both rheological and coagulative abnormalities contribute to vascular occlusion and subsequent ischaemic and proliferative events. To date therapeutic manipulation of rheological and coagulative events has not had a significant place in the management of diabetic retinopathy.
Altered vascular cell kinetics
The survival of cells during severe and sustained hyperglycaemia depends on internal factors such as proper transcriptional! translational regulation, an acceptable synthetic capability, fully integrated metabolic pathways and intact plasma membranes. External signals from the extracellular matrix and paracrine secretions from adjacent cells coupled with systemic endocrine stimulation are also essential elements of cell regulation and survival.
Abnormal metabolism of the cell may be heralded by changes in gene expression modulated by DNA damage, accumulation of inappropriate metabolic products, biochemical perturbations and altered turnover of cell components. At a cellular level, hyperglycaemia can either directly or indirectly influence cell proliferation, migration and angiogenesis on the one hand or cell dysfunction and death on the other.
Cell proliferation/migration
Ordinarily retinal vascular cells are quiescent (Go stage of the cell cycle) with a very low level of endothelial cell and pericyte replication required only to make good wear and tear damage to the vascular lining?O In severely diabetic animals retinal vascular endothelial cell turnover is markedly increased although pericytes show significantly less replicative capacity?O Focal endothelial cell proliferation probably occurs in ischaemic retinopathy as some defunct channels recanalise and new vessels form. These are categorised clinically as intraretinal microvascular abnormalities (IRMAs) and are a feature of significant inner retinal ischaemia and a risk factor for the development of preretinal and papillary new vessels. Migrating endothelial cells can occasionally be observed in vivo, in the act of proteolytic ally digesting and breaching their basement membranes, and in proliferating preretinal new vessels the endothelial cells are highly active and have few pericyte contacts (Fig. 8 ). Activated and migrating endothelial cells require an appropriate balance of local growth factors and their specific receptors, access to low resistance pathways and specialised interaction with the extracellular matrix. 
Apoptosis
Apoptosis is a genetically 'programmed' and controlled form of active death, which in most cell types relies on a constitutively expressed, but normally inactive, death machinery?03, 1 04 Although many induction pathways have been identified for apoptotic cell death the central 'executioner' is now thought to be a complex interaction of a cascade of cysteine proteases (caspases) and other factors released from dysfunctional mitochondria. l OS Apoptosis may be likened to cell suicide and results from activation of the death apparatus, either by withdrawal of survival signals, or by receipt of death commands. Failure of affirmative stimuli mediated by auto-or paracrine cell-specific growth/ survival factors, or loss of normal matrix interactions through, for example, integrin receptors, may induce apoptosis by default. Alternatively, receipt of exogenous death-inducing signals through receptors of the TNF family may have the same result. Death stimuli such as ROS may also arise internally, for example as a result of DNA damage detection mediated by the p53 transcriptional factor. 1 06 Apoptosis is typified by distinctive morphological signs which include cell shrinkage, extreme condensation of the nuclear chromatin and blebbing of the plasma membrane with the associated dissection of the cell into membrane-bound packets or apoptotic bodies (Fig. 4B) . Although apoptotic bodies may be engulfed by 'professional' phagocytic cells such as macrophages, they are also internalised by the normal neighbours of the 
Necrosis
In contrast to apoptosis necrosis is usually considered a passive degeneration induced by overwhelming toxic or physical insults, often by the same agents which at lower levels may induce apoptosis, e.g. ionising radiation. In necrosis the gross morphological changes are diametric to apoptosis with uncontrolled swelling of the cell cytoplasm and intracellular organelles. Dominant in this process is the rupture of lysosomal compartments with release of acid hydrolases. Necrotic cells also experience a rapid loss of plasma membrane integrity, with release of pro-inflammatory cell products into the tissue spaces. This precipitates a localised inflammatory response and activates scavenging systems in the retinal neuropile to remove redundant and non-functiOning cell debris.
Although certain oxidative events, perhaps mediated by dysfunctional leucocytes, can be sufficiently acute to overwhelm retinal vascular cells and induce necrosis in diabetes, it seems more likely that prolonged hyperglycaemia-associated cellular dysfunction and disruption of survival signals through glycation of the extracellular matrix predispose to an apoptotic death scenario.
Functional changes
The retinal vasculature is well designed to satisfy the high metabolic and respiratory requirements of the inner retina and maintain strict control over the biochemical balance of the extracellular space of the retinal neuropile. It reacts flexibly to changes in the systemic circulation such as reduced blood oxygen saturation, hypercapnia and hypertension and responds swiftly to altered circumstances in local tissue metabolism, i.e. autoregulation of blood flow. The retinal microcirculation with its high endowment of smooth muscle cells and pericytes modifies blood flow according to local tissue needs and intrinsic autoregulatory processes are controlled by upstream haemodynamic events via the release of vasoactive agents. The retinal vascular endothelium is a key player in controlling blood flow by virtue of its direct and indirect ionic, biochemical and physical contacts with adjacent pericytes in capillaries, and smooth muscle cells in arterioles.
Sustained hyperglycaemia influences many aspects of retinal vascular function, particularly autoregulation of blood flow, permeability and local rheology.94,107-110 However, changes are potentially reversible in early diabetes and generally not sufficient to compromise necessary visual functions prior to significant cell loss, vascular occlusion and development of retinopathy.
Blood flow alterations
Vascular control in early diabetes is probably affected by oxygen need and the interplay of various vasoactive substances whose release and effects may be altered by aphysiological glycaemia?2 NO, a vasodilator, and ET-l, a potent vasoconstrictor peptide, are probably the key players in controlling vessel calibre and blood flow in the retinal circulation,22,11 9-124 although other metabolites such as prostacyclin, thromboxane A 2 and other eicosanoids may contribute to haemodynamic change.22 Adenosine, which accumulates under hypoxic and ischaemic conditionsps causes relaxation of pericytes through the activation of its A 2 receptors and it has been proposed that adenosine may contribute to the 'fine tuning' of the retinal circulation.126 Insulin may also be associated with retinal vasodilatation through NO release and modification of Ca2+ channels and/ or regulation of endothelin-1 (ET-1) expression. Most studies show that hyperglycaemia inhibits retinal pericyte contractilityY7
ET -1 and ET -3 secretion is increased in retinal microvascular endothelial cells exposed to high glucose concentrations in vitro and in the vascular endothelium of diabetic rats.123,12S ET-1 and ET-3 induce pericyte contraction and constriction of small arterioles, although when conditioned to a glucose-rich environment pericytes become somewhat resistant to ET -1 as demonstrated by impaired contractile responsesY9,121,12 9 It has also been shown that intravitreal injection of ET -1 and ET -3 reduces blood flow in diabetic rats121 and blockade of the ETA receptor, which mediates the constrictor effects of ET -1, normalises retinal blood flow. It is likely that an increase in endogenous expression of ET-1 and ET-3 contributes to the reduction of retinal blood flow reported in the early stages of diabetes. 124 Inadequate blood flow, hypoxia and hypercapnia potentiate the production of NO and adenosine which relaxes pericytes and smooth muscle cells.22 It has been suggested that these two agents normally maintain the retinal vasculature in a tonic state of mid-dilatation. The precise biochemical events leading to alteration in the release of vasoactive substances in hyperglycaemia are still ill-understood; however, it has recently been proposed that elevated DAG and the resultant sustained activation of PKC-f3II in hyperglycaemia represents a major causative factor in the abnormal retinal haemodynamics in diabetic rats. This proposition is consistent with the central role of PKC in the transduction pathways of vasoactive agents such as ET-l and NO. Thus, it can be appreciated that changes in retinal blood flow in early diabetes follow disruption of the physiological balance between competing vasoactive agents.
In chronic diabetes other systemic haemodynamic factors become important such as abnormal blood rheology, and increased leucocyte adhesion to the vascular endothelium which conspire to increase vascular resistance to flow.130 Once structural changes occur in the retinal vasculature, particularly basement membrane thickening and loss of pericyte and smooth muscle cells, the capillary bed becomes unresponsive and autoregulative capacity gradually fails. Subsequent occlusion of capillary beds and development of preferential pathways may result in uncontrolled blood flow and further haemodynamic insult to the residual vasculature.
Altered vascular permeability
Increased retinal microvascular permeability is a feature of established diabetic retinopathy and chronic accumulation of extracellular fluid at the macula is a common cause of visual impairment in both insulin dependent and non-insulin-dependent diabetes. The retinal pigment epithelium appears more durable in diabetes than the retinal vascular endothelium and although some outer barrier failure has been described in diabetic patients131 it is probably not an important factor in the genesis of early maculopathy.
The point in the diabetic process at which the normally 'tight' retinal microcirculation becomes excessively permeable is not known, although early vascular incompetence has been reported in diabetic and galactosaemic animal models using tracers and in some pre-retinopathic diabetic subjects using vitreous fluorophotometry.132 Subtle alterations in microvascular permeability are difficult to discern clinically, as gratuitous fluid in the extracellular space may be expeditiously removed by vascular endothelial and retinal pigment epithelial Na + /K+ -ATPase pumps. However, when leakage overwhelms the compensatory mechanisms fluid accumulates in the retinal extravascular and extracellular spaces and increased retinal thickness can be detected biomicroscopically and quantified with ultrasound or scanning laser techniques.
The cellular basis for increased vascular permeability in diabetes is undecided; however, it is probably a combination of failure of the occluding intracellular junctions/33,134 heightened transendothelial fluid dynamics and enhanced vesicular transport. 135 In advanced disease, fenestration of the normally 'tight' vascular endothelial cells may occur136 and in some damaged capillaries, i.e. microaneurysms, there is complete loss of endothelial integrity. Increased vascular permeability may also reflect abnormal expression of vasopermeability factors (e.g. VEGF or histamine) and untoward haemodynamic events such as venous occlusion. The modified chemistry of the microvascular environment together with altered pericyte and glial cell function may also influence the permeability characteristics of the inner blood-retinal barrier.
Hae modyna mic stresses
Capillary endothelial competence and integrity may be challenged by increased hydrostatic pressure due to failure of the upstream pre-capillary arterioles to regulate blood flow. Loss of smooth muscle cells in pre-capillary arterioles16 and impaired autoregulation may impose unsustainable shear stresses on the downstream delicate and unprotected capillary bed. Uncontrolled blood pressure, increased turbulence and shear stress and exaggerated blood viscosity can physically elongate vascular endothelial cells and increase their permeability?6.137-139 Similarly venous occlusion or stasis may cause an immediate outpouring of fluid due to increased hydrostatic pressure, coupled with an associated hypoxic or ischaemic environment. Increased permeability following vein occlusion may be more a function of the hypoxic insult than the sustained elevation of hydrostatic pressure. Vascular dilatation associated with the unstable circulation of advanced retinopathy also vastly increases the capillary surface area to be serviced by the vascular endothelium and stresses both their intracellular junctions and cell barrier functions. Whether retinal capillaries suffer significant shear stress damage in diabetes is unproven.
Growth fa ctor influences
It is becoming increasingly recognised that vascular permeability can be dramatically altered by the local action of growth factors, hormones and intraocular inflammatory mediators on the microvasculature. Various growth factors and cytokines can alter vascular permeability as illustrated by the intravitreal injection of insulin-like growth factor (IGF-l) which can cause profound changes to the structure and permeability of normal retinal vessels in experimental animals. 140 Growth factors such as b-FGF, epidermal growth factor (EGF), TGF-f3 and platelet-derived growth factor (PDGF) all have established and important biological effects on the normal function and survival of retinal vascular and paravascular cells (Fig. 9 ). Their precise role in the evolution of diabetic retinopathy is unclear at present. VEGF, formerly known as vascular permeability factor (VPF), is a ubiquitous, pluripotential growth factor, expressed by vascular, neuronal and glial cells141 and strategically placed to influence microvascular form and function and act as a survival factor for retinal vascular endothelial cells.142 It is fast being recognised as a key growth factor involved in the genesis of both exudative and proliferative diabetic retinopathies.143-145 VEGF is a glycopeptide with sequence homology to other members of the VEGF family which include VEGF B,C,D, placental growth factor and PDGF and binds with high affinity to specific tyrosine kinase receptors (Flt-l and KDR) on vascular endothelial cells. VEGF undergoes alternative mRNA splicing to yield at least five isoforms, several of which bind to heparin sulphate proteoglycan, a key component of basement membranes. VEGF may act in a paracrine or autocrine fashion and by virtue of its basement membrane binding properties is concentrated at the endothelial/pericyte interface. Hyperglycaemia increases the production of VEGF45 in the retina, particularly by retinal vascular endothelial cells, pericytes, smooth muscle cells, retinal pigment epithelial cells and neuroglia,z7,146,147 Hyperglycaemia induced VEGF gene expression and peptide production in human smooth muscle cells has been shown to be mediated by a PKC-dependent mechanism.148 Crucially, VEGF expression is triggered by hypoxia,89, 92 ,14 9 ,150 probably mediated by adenosine123 through transcriptional regulation by HIF-la, and decreased in conditions of hyperoxia.15I The biological effects of VEGF are dictated by the nature of its source cells, the levels secreted and the receptor expression by target cells. Known pathophysiological effects of VEGF are neovascularisation and increased permeability of blood vessels, and it also appears to have key roles in vascular cell survival and maintenance of phenotype in fenestrated endothelia such as choriocapillaris, renal glomerulus and choroid plexus,89,150,152,153 vascular cell survival and angiogenesis. 89 More recently VEGF immunoreactivity has been correlated with increased vascular permeability to macromolecules,153 i.e. extravasated albumin in human diabetic retinae, and permeability appears to be increased in diabetic patients before the onset of clinically apparent retinopathy.143 It has been demonstrated that exogenous VEGF induces a fenestrated phenotype in endothelial cells of normally non-fenestrated dermal capillaries154 and that these changes can be inhibited by anti-VEGF monoclonal antibodies. In proliferative diabetic retinopathy VEGF is highly expressed in the vitreous and in the immediate vicinity of preretinal new vessels which are highly permeable to macromolecules and declines following panretinal laser photocoagulation. 155, 156 It is also likely that retinal-pigment-epithelial-generated VEGF sustains the fenestrated choriocapillaris necessary for the transport of vitamin A to the outer retina. Loss of retinal pigment epithelium cells and choroidal infiltration by glia can result in the contiguous choriocapillaris becoming non-fenestrated. 157 Thus it seems that the retinal capillary endothelium can alter its phenotype according to local concentrations of VEGF.
Endothelial dysfunction
Increased vascular permeability in early diabetes probably represents an exaggeration of normal cell transport mechanisms and increased facility for fluid movement between intercellular tight junctions.I S S Gardner et al.158 point out that histamine and VEGF increase vascular permeability, and reduce expression of one of the major endothelial junction zonula occludens proteins (ZO-l) allowing excess intercellular fluid leakage.134 Antihistamines have been shown to reduce the leakage of blood vessels in diabetic rats and clinical trials are under way to determine their effectiveness in exudative maculopathy. In more advanced diabetes the unrestricted passage of macromolecules indicates a serious failure of vascular endothelial function and may reflect a change in the structure and phenotype of those endothelial cells which have grossly thickened basement membranes and loss of pericytes. 136 
Endocytosis
Retinal vascular endothelial cells exposed to a high glucose medium (25 mM) in culture show an increased uptake of tracer (HRP) from the medium by a pathological increase in the level of receptor-mediated endocytosis. Short-term diabetic animals also demonstrate a similar increased endocytosis in the retinal vasculature.159 This exaggerated endocytotic effect can be ameliorated by anti-glycation agents such as D-lysine and aminoguanidine, suggesting that the increased endocytosis is an attempt by the cell to replenish its plasma membrane components and receptors which are perceived by the cell as damaged or senescent due to glycation. 160 It is conceivable that in diabetes, glycation of cell membranes interferes with normal plasma membrane recycling and receptor mediated transport of macromolecules.
Altered endothelial cell morphology: fe nestrations
The morphology and structure of vascular endothelial cells can be altered by haemodynamic forces, chronic inflammation, chemical mediators (histamines, prostaglandins) and growth factors IGF-1 and VEGF, with subsequent changes in form and permeability. In established diabetic retinopathy vascular endothelial cells can be grossly attenuated in areas of exudation and display increased intracytoplasmic vesicles and plasma membrane fenestrations.136 Incidentally retinal venules with grossly thickened basement membranes may also become fenestrated, possibly due to a dilution of barrier maintaining effects of the displaced paravascular glial cells. 161 Retinal new vessels display no immunoreactivity for GLUT I, which is in keeping with their fenestrated endothelium, loss of selective permeability162 and lack of any imperative for facilitated glucose transport.
Once the retinal vascular endothelium loses its barrier functions other factors come into play. Accumulations of blood-borne proteins and lipids exert osmotic, oxidative and pro-inflammatory effects and altered storage of growth factor in the sclerotic basement membrane may have an exaggerated influence on a labile vascular endothelium.
Structural changes
Basement membrane thickening
Retinal vascular basement membranes not only provide structural support for the endothelial cells but also regulate cell adhesion, migration, differentiation and significantly influence proliferation. Retinal vascular basement membrane thickening is the first and most predictable histopathological change observed in human and experimental diabetes (Fig. 10) . 163 All vascular radicals are affected, particularly the microvasculature on the arterial side of the circulation,164 and measurable changes are present after only a few months of experimental diabetes. 165 Increased synthesis of collagen IV, fibronectin and laminin by endothelial cells and pericytes under the influence of hyperglycaemia and AGEs adds to the bulk of the basement membrane. [166] [167] [168] Furthermore advanced glycation of long-lived matrix proteins impedes their degradation by catabolic enzymes78 leading to a net increase in basement membrane thickness?5 In diabetes the thickened basement membrane becomes cross-linked, rigid and poorly compliant and may physically restrict capillary contraction and dilatation. Exaggeration of heparin sulphate proteoglycan synthesis also adds to the structural and biochemical complexity of the basement membrane affecting its ligation of key vasogenic, heparin-binding growth factors such as VEGF and bFGF. Extraneous endothelial cell and pericyte by-products and uncensored proteins from the circulation such as immunoglobulins and oxidised and/ or glycated macromolecules may penetrate the increasingly permeable endothelium to become entrapped in the basement membrane complex, further complicating its chemistry and filtration role.
The thickened basement membrane may impede pericyte / endothelial cell contacts, interfere with cell signalling and diminish the inhibitory influence of pericytes on vascular endothelial cell proliferation. The separation of the vascular complex from neighbouring glial cells may also have consequences for endothelial cell structure and permeability.136,157 Excess or abnormal deposition of basement membrane proteins may also serve to disrupt the nature of complex cell-matrix interactions and influence their capability to spread, migrate and replicate.167 Oxidation, glycation and polyol pathway overactivity have been implicated in the pathogenesis of basement membrane thickening and ARIs and anti-glycation agents may prevent or moderate basement membrane thickening in experimental diabetic and galactosaemic animals.169
Pericyte loss
The premature and selective loss of pericytes is the cellular hallmark of diabetic retinopathy and probably represents a key event in deciding subsequent microvascular instability, decompensation and collapse.170,171 Pericyte loss is evident in human diabetes of about 10 years' duration, in diabetic dogs at 4-5 years and diabetic rats at 6-8 months (Fig. 10) . The exact cause of pericyte demise is still unknown, but is probably the result of varied and cumulative biochemical insults coupled with the limited ability of the cell to repair and renew itself. Elevated glucose levels can directly inhibit pericyte cell growth25 and contraction120,127 and both hyperglycaemia and abrupt reduction in extracellular glucose can cause oxidative stress and induce apoptosis. 68 Sustained hyperactivity of the polyol pathway and subsequent metabolic disturbances may contribute to pericyte malfunction and death by aphysiological accumulations of sorbitol, pseudohypoxia and altered functions of key enzymes such as PKC and Na + /K+ -ATPases. ARIs go some way to preserving pericytes in diabetic and galactosaemic animals and possibly prevent some of the later microvascular complications, although this remains controversial and may be influenced by the efficiency of the ARI used or the nature of the diabetic animal model. Clinical trials of ARls launched on the basis of such experimental studies have not, thus far, shown that they prevent the onset of clinical diabetic retinopathy.
Pericytes may also be particularly susceptible to glycation. Pericytes express AGE receptors and Stitt et al. 80 have shown that after 8 weeks of diabetes in the rat there is a striking accumulation of intracytoplasmic AGEs, whereas endothelial cells display only modest concentrations (Fig. 11) .80 Why AGEs should accumulate preferentially in pericytes is not known, although experimental studies have shown that AGEs have toxic effects on pericyte growth and function l7 2 and anti glycation agents such as aminoguanidine prevent their loss in diabetic animals. 1 7 3 Widespread pericyte loss will affect capillary tone and contraction and influence local blood flow control and possibly alter vascular permeability. Loss of pericyte/ endothelial cell contact may alter endothelial cell reactivity due to loss of the pericyte cell inhibitory influence through TGF-f3. As pericytes are central to normal functioning of the capillary any pharmacological intervention to preserve them in diabetes would have a material effect on the development of later microvascular complications.
Smooth muscle cell depletion
Smooth muscle cell loss in retinal arterioles occurs about the same time as pericyte death in diabetic dogs and has also been noted in human retina (Fig. 12 ). Smooth muscle cell depletion has also been overshadowed by the more discernible pericyte loss and has only recently been highlighted by Gardiner et al. 16 Smooth muscle cell loss in pre-capillary arterioles has major implications for autoregulation of the downstream capillary bed and endothelial cell permeability and survival. Loss of smooth muscle cells and pericytes is probably linked as both cell types demonstrate high polyol pathway activity under conditions of hyperglycaemia and respond biochemically to ARIs. In common with pericytes, arteriolar smooth muscle cells have been shown to bear AGE receptors and accumulate these adducts in diabetes or after exposure of non-diabetic animals to exogenous AGE-modified albumin. s o
Va scular endothelial cell loss
The cause of early endothelial cell failure is ill understood, although loss of integrity of the vascular endothelium with platelet deposition on the exposed basement membrane and activation of the clotting cascade is the most likely sequence of events leading to early capillary closure. Endothelial cell death may follow inexorable metabolic duress or failure of endothelial cell division and migration to make good defects in the capillary lining, especially in dilated channels where the luminal endothelial surface area is greatly increased and in microaneurysms. 1 7 4 Va scular occlusion and recanalisation
The insidious early occlusion and atrophy of capillaries is a feature of both insulin-dependent and non-insulin dependent diabetes and is observed in human diabetics and galactosaemic/ diabetic animals in the absence of retinopathy. 1 7 5 The natural course of vascular occlusion in diabetics is unpredictable and varies from subtle and inconsequential capillary fallout to inexorable and severe collapse of the microvasculature and the subsequent sequelae of an ischaemic retina. The exact cause of capillary occlusion is still not known, although there are numerous precipitating factors including haemodynamic stress, endothelial cell loss and reduction of intraluminal pressure below the capillary critical closing pressure. Altered local coagulability of blood in tandem with up regulation of adhesion molecules and leucocyte activation may also precipitate capillary occlusion and fibrin locking of juxtaposed endothelial cells.95,98, 1 7 6 Such a scenario usually presents in advanced or end-stage diabetic retinopathy where there is severe circulatory stasis and damaged neuropile. Inflammatory cells, particularly monocytes and neutrophils, are consistently present in retinal microaneurysms and recanalised vessels. 1 7 4 Acellular and occluded capillaries (and larger vessels) persist as redundant, non-functional basement membrane tubes, and have been labelled 'ghost vessels'; however, some defunct channels are re-endothelialised and may become serviceable if connections are achieved with a viable circulation (Fig. 12) . These channels generally traverse ischaemic inner retina and may be associated with increased VEGF levels. Most refurbished capillaries have a high complement of inflammatory cells (especially macrophages) and these are the likely source of angiogenic growth factors.
Neovascularisation
Ischaemic and putatively hypoxic retina is a strong stimulus for intra-and extraretinal neovascularisation. 176 Intraretinal neovascularisation is usually a muted reponse and is clinically manifest as IRMAs. It is often difficult to decide clinically whether IRMAs are de novo new vessels en route to extraretinal neovascularisation or occluded capillaries which have re-endothelialised (Fig, 12) . Most new or reconstituted intraretinal vessels have a continuous 'tight' endothelium with permeability characteristics more reminiscent of normal vessels than new preretinal vessels. Whether they are functionally provident is not known.
Most classical new retinal vessels originate from veins or venules and rapidly access the preretinal space where their future development is determined by the physical constitution of glycated vitreous and the preretinal concentration of various growth factors. 
l S I
The required cocktail of growth factors to induce and sustain intra-and preretinal neovascularisation is being intensively investigated, although VEGF is rapidly assuming primacy as the key angiogenic factor.91,IS2,183 VEGF is hypoxia-sensitive and the peptide expression is elevated in the vicinity of new vessel complexes. VEGF levels are also elevated in the vitreous of patients with preretinal neovascularisation and in the aqueous of individuals with neovascular glaucoma.183,184 The putative role of other members of the VEGF family is a growing area of interest, since VEGF-B,C,D and placental growth factor share structural and functional homology with VEGF itself. Indeed, basic and acidic FGF,185-187 PDGF, EGF, IGF_1,76,188 TGF-f3,189 hepatocyte growth factor and a variety of interleukins must all be included in the angiogenic equation.190 IGF-1 has been highlighted as a key culprit in exacerbating neovascularisation in those poorly controlled diabetics, entering strict glucose control regimens (normoglycaemic re-entry phenomenon).
The natural course of preretinal new vessels tends to be cyclical, progressing from rapidly advancing fronds to established vascular complexes with competent feeding channels and ultimately to atrophic acellular strands with high complements of supporting collagen and glial tissue. In end-stage disease the balance of growth factors has changed decisively in favour of growth inhibitors such as TGF-f3. There is a constant interplay of growth factor effects at the outer retina and preretinal space, even in patients with no diabetic retinopathy. Mitchell et al . 191 have shown that some 10% of diabetic patients with no retinopathy develop clinically detectable preretinal membranes subsequent to the proliferation of fibroblasts and glial cells. Opportunities for biochemical manipulation of retinal neovascularisation are fast becoming a reality if not a practical proposition.
Therapeutic options
Prevention of retinopathy
Maintaining euglycae mia
The objective in potentially diabetic patients is to anticipate and abort the disease process. In type I diabetics the auto-immune disease process that leads to the destruction of insulin-secreting pancreatic islet f3 cells may be tempered or abated by early insulin treatment. 192 Nicotinamide and immunosuppressive therapy may salvage functioning f3 cells and induce remission or delay in the onset of diabetes in antibody-positive children.1 93 Nevertheless, most current opinion holds that potentially toxic therapy should only be offered where the onset of diabetes can be predicted with 'near certainty' and the search for predictive clues, such as presence of insulin antibodies and genetic markers, proceeds apace. Some predictive models offer a 90% probability of positive individuals progressing to insulin therapy within 3 years and suggest that the remaining 10% of patients will almost certainly follow the same route with time. 194 In type II diabetics, in whom there is only a relative tissue insulin deficit, prevention is largely directed at reducing insulin requirements (e.g. controlling obesity) and increasing insulin sensitivity at the receptor level in patients with a genetic predisposition to the disease process.
Re-establishing euglycae mia
In established diabetics the early, complete and permanent restoration of euglycaemia is the best guarantee that retinopathy will not develop. Pancreatic transplantation is now a practical proposition for insulin dependent diabetics, but requires long-term immunosuppression and at present this procedure is the preserve of specialised centres and is generally offered only to diabetics with advanced disease and secondary complications such as end-stage nephropathy.195,1 96 Even where euglycaemia is achieved there is little recovery of entrenched retinopathy or visual gain. [197] [198] [199] Islet cell transplantation with portal seeding of purified f3 cells is also feasible and less invasive, and in a few patients satisfies all their insulin needs. Nevertheless, life-long immunosuppressive therapy is still mandatory and the harvesting of sufficient numbers of pure and functioning cells to establish euglycaemia presents special logistical problems?OO
Achieving 'near' euglycae mia
For most diabetics at this time the immediate goal is to achieve near euglycaemia and moderate those risk factors which may potentiate or aggravate vascular disease, such as hypertension,35,201 smoking, hyperlipidaemia and anaemia.9 The advantages of good and long-term diabetic control have been highlighted by recent and exhaustive trials for both insulin-dependent33 and non-insulin-dependent diabetics,1O,201 and the introduction of new insulins, novel administrative techniques and improved programmes of care are helping to achieve this objective. For type II diabetics other therapeutic avenues exist to ameliorate but not cure hyperglycaemia, such as reducing gastrointestinal glucose absorption and utilisation. Clinical diabetes may also be improved by increasing insulin sensitivity, improving f3 cell function at a cellular level or moderating insulin need by weight reduction and exercise. 202 The quest for near euglycaemia, although laudable, has the potential for inducing acute, recurrent and even prolonged hypoglycaemia in insulin-dependent diabetics?03 Hypoglycaemia may trigger the release of potent vasoconstrictors such as adrenaline, vasopressin and angiotensin II, alter blood coagulability and viscosity and activate neutrophils with the combined effect of damaging capillary endothelium, inducing capillary closure and exaggerating proliferative retinopathy. Relative 'hypoglycaemia' following acute normalisation of blood glucose levels in ill-controlled diabetics (re-entry phenomenon) may cause sudden intensification of an ischaemic retinopathy and has been attributed in part to increased IGF-l levels. It is important to monitor the retinopathic progress carefully in such patients and if necessary to undertake a pre emptive strike with laser photocoagulation in patients with pre-proliferative or early proliferative retinopathy.
Junctional
Li miting adverse bioche mical processes
In the absence of a cure for diabetes, or guaranteed euglycaemia, the best prospect for preventing retinopathy or extending the time to presentation lies with the correction or moderation of those biochemical processes which lead to retinal vasculopathy (Fig. 13) . The better understanding of hyperglycaemia-linked biochemical processes which damage vascular cells and the parallel development of pharmacological agents to prevent or limit such reactions now presents an unprecedented opportunity to make some impact on the pre-retinopathic disease process in diabetes. It has been demonstrated in established diabetic or galactosaemic animals that development or progression of retinopathy can occur despite normalisation of glycaemic contro1204 or withdrawal of galactosaemic diet/OS so early institution of effective therapy seems crucial in stemming the microvascular disease process,z06
As only a proportion of diabetics develop sight threatening retinopathy and some of the putative anti retinopathic drugs have known or potential side-effects, there is now a clear imperative to identify those diabetics likely to proceed to significant retinopathy, before irreversible changes have occurred to vascular cells. Apart from insulin and oral hypoglycaemic agents no drugs to date have shown an unequivocal and durable effect in preventing, stabilising or reversing diabetic retinopathy. Some pharmacological preparations, however, hold promise for correcting abnormal metabolic functions at a tissue culture and experimental animal level and some preparations are currently being assessed in clinical trials. Other potential therapeutic agents are at a conceptual level but hold exciting possibilities for the future.
Anti-oxidants. The exaggerated oxidative processes in diabetes, coupled with a reduction in anti-oxidants, would suggest that dietary supplementation with anti oxidants might be helpful. It has been shown that vitamins C and E reduce concentrations of oxidised low density lipoproteins (LDLs) and increase NO production with favourable effects on retinal blood flow, and coincidentally on any existing hypertension,z°7 Vitamin E, in addition to its anti-oxidant properties, inhibits the changes in DAG level and PKC-J3II activation induced by high glucose in cultured cells.20B Vitamin E supplements in diabetic rats can also prevent abnormalities in retinal blood flow,zo9 It has also been proposed that a-lipoic acid might improve retinal haemodynamics; however, despite the compelling logic of vitamin therapy there is no clear evidence that supplements favourably influence the course of diabetic retinopathy. One recent epidemiological study reported that no protective effect was observed with anti-oxidant nutrients vitamins C, E and J3-carotene,71 although in interpreting these findings it should be noted that J3-carotene is not an anti-oxidant and that vitamin C may be pro-oxidant in some situations.
Aldose reductase inhibitors. The recognition that polyol pathway overactivity produces adverse biochemical reactions in retinal vascular cells led to the use of ARIs to forestall the development of diabetic retinopathy. ARIs diminish basement membrane thickening and conserve pericytes in the retinal microvasculature of some diabetic and galactosaemic animals, especially in galactosaemic models where retinal galacticol concentrations are particularly high210 (galacticol is not metabolised further by polyol dehydrogenase, in contrast to sorbitol); however, Engerman and Kern48 found that the ARI sorbinil did not significantly influence the development of retinopathy in either diabetic or galactosaemic dogs.
The ARI-509 prevents expression of VEGF in galactosaemic rats211 and some early clinical studies reported that ARIs improve capillary permeability in non-retinopathic diabetics,212 but to date no randomised control trial has shown that these drugs have any observed clinical effect on the onset of diabetic retinopathy.47 Frank213 and others have highlighted the fact that ARI trials have not been initiated at or near the time of diagnosis of diabetes and that many patients may have irreversible structural changes already present in the retina which do not yield to ARI therapy.
ARIs can slow, but not reverse, the progression of diabetic polyneuropathy and autonomic neuropathy and some workers believe that their failure to influence diabetic retinopathy may reflect the nature and concentration of the inhibitor used and length of time of the trial and that differently constructed trials may demonstrate a therapeutic benefit. 55 Protein kinase C-J3II blockade. PKC-J3II is involved in modulation of VEGF receptor signal transduction cascade and the specific inhibition of this isoform is able to prevent the proliferation of endothelial cells induced by VEGF. PKC-J3II activation can affect a wide range of vascular functions in diabetics, including permeability, coagulation and blood flow. Recent evidence that specific blockage of PKC-J3II using LY333531 can reverse abnormal haemodynamics in diabetic animals raises the possibility of influencing the disease process at a pre retinopathic stage.56,60 LY333531 can also decrease new vessel formation in pigs with experimental branch retinal vein thrombosis?14 PKC-J3II inhibition seems to have few adverse side-effects and clinical studies are under way to establish its effectiveness, Anti-glycation agents. Glycational processes culminating in the intra-and extracellular accumulation of reactive end-products and cross-linked proteins can affect the form and function of vascular cells and their extracellular matrices in established diabetes. There is a positive relationship between the incidence and progression of diabetic retinopathy and levels of HbA 1 e and it has been demonstrated that some of the pathological glycational processes can be prevented or minimised by anti glycation drugs in diabetic animal models, 160, 173, 215, 216 suggesting therapeutic applications in the clinical setting. Anti-glycation agents such as aminoguanidine may also inhibit NO synthesis and reduce dysfunction induced by elevated NO levels in diabetes}17 and Stitt et al. 178 have used aminoguanidine to reverse vitreous cross-linking mediated by AGEs.
Aminoguanidine, the best-characterised anti glycation agent, improves peripheral nerve and retinal electroretinographic function in experimental diabetic animals and reduces basement membrane thickening and pericyte dropout,173,180 and is now the subject of phase III clinical trials in diabetic patients. Other anti glycation agents are currently under development; however, there are still unanswered questions about the best time of such intervention in the retinopathic process, optimum dosage, appropriate patients and whether functional benefits outweigh any long-term toxic reactions or adverse effects.
Recently formulated ' AGE-breakers' have proved effective at a molecular level in preventing cross-linking of glycated proteins. Whether any of these novel drugs will prove effective in treating patients is not known but is a consideration for the future? 16 Angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, anti-coagulants, antihistamines and aspirin.
It has been reported that certain angiotensin I-converting enzymes (ACE) inhibitors, such as captopril, are protective against retinopathy, nephropathy and neuropathy in insulin-dependent diabetic patients, irrespective of the presence of hypertension and that they can improve microvascular complications and delay or reverse diabetic retinopathy. 218 The mode of such putative action is still unclear; however, some studies demonstrate a restoration of depressed Na + /K+ -ATPase levels in diabetic animals to norma1.53,21 9 Improved blood flow may reflect reduced ACE activity or increased bradykinin levels with associated formation of NO?20 It is also speculated that calcium-channel blockade may improve retinal vascular dysfunction in diabetics by improving vascular permeability and possibly countering vascular occlusion by modulating smooth muscle contraction.221 The control of hypertension by both ACE inhibitors and calcium blockers should als. o have a favourable effect on the development of diabetic retinopathy. It would be anticipated that aspirin with its anti-coagulant effects should improve the natural course of diabetic retinopathy, especially in the face of capillary occlusion and thrombosis. However, the ETDRS222 did not find any beneficial effects of aspirin (650 mg/ day) in retarding the progression of pre-proliferative or early proliferative retinopathy or macular oedema. Alternatively, aspirin did not worsen the risk of vitreous haemorrhage in relatively advanced diabetic retinopathy. Whether early intervention with aspirin retards the development of early retinopathy or minimises capillary fallout is not known.
Histamine reduces the expression of 20-1, a major tight junction protein of vascular endothelial cells, and increases vascular permeability. In preliminary studies in humans antihistamines increase barrier functions. 223 Antihistamines are now being tested in view of their putative positive effect on retinal vascular permeability.
Management of vascular complications
Exudation: oede ma
The pharmacological reversal of microvascular incompetence, especially macular oedema, would be a signal advance in the management of diabetic patients as the current established treatment of laser photocoagulation is both destructive and of doubtful use in ischaemic and cystoid macular oedema. There is now growing evidence that increased concentrations and altered balance of certain growth factors can alter vascular permeability and that regulation of expression, secretion and target cell receptors may improve permeability and vascular function. Suppression of VEGF activity by antibodies and PKC-j3II isoform inhibitors can enhance barrier functions in experimental diabetes224 and microvascular incompetence induced by intravitreal injection of IGF-1 can also be abolished by neutralising pharmacological actions. New techniques are becoming available whereby therapeutic agents, such as biodegradable polymers containing co-drugs (e.g. fluorouracil)}25 . 226 can be introduced into the vitreous cavity to control cell growth in experimental animals and it is only a matter of time before acceptable anti-VEGF agents become available for therapeutic evaluation. When considering such an approach it must be remembered that VEGF is a potent survival factor15 2 and inhibition or attenuation of its production in a severely compromised retinal vasculature could have adverse effects.
Vascular ocd usion: revascularisation
In diabetics, vascular occlusion tends to be insidious, progressive and irreversible. Some re-endothelialisation and recanalisation of defunct channels does occur and limited intraretinal neovascularisation may take place, but return of function to ischaemic retina is insignificant and the use of neuroprotective agents, such as nerve growth factor}27 even if feasible, is unlikely to make a material difference to survival of neurones and vision. It has recently been shown that acidic and basic fibroblastic growth factors (aFGF, bFGF) injected into the ischaemic myocardium of patients with ischaemic heart disease can revascularise the impoverished tissue and improve cardiac functions?28 It is possible that limited reperfusion of ischaemic retina may be achieved with receptor analogues and/ or growth factors that aid survival of vascular cells, facilitate their replication and migration or improve their interaction with substrates, especially defunct basement membrane tubes. The challenge now is to encourage by pharmacological means the recanalisation of defunct and acellular capillary beds and establish a viable circulation without the process extending to the formation of preretinal new vessels.
Neovascularisation
The development of retinal neovascularisation in diabetes is a poor prognostic sign for vision and retinal integrity and an important indication for panretinal photocoagulation. The ability to prevent and manipulate new vessel growth would not only improve the survival of the retina and avoid laser-induced atrophy of the neuropile, but in a wider biological sense have important implications for the treatment of cancerous lesions which are dependent on a blood supply.
VEGF is now the focus of most experimental therapies aimed at inhibiting ocular neovascularisation 229 .23o and preretinal neovascularisation in the hyperoxia-treated mouse model can be suppressed by intravitreal injection of VEGF antisense 0ligonucleotides?31 It has also been shown that VEGF levels fall dramatically in the vitreous following panretinal laser photocoagulation for proliferative diabetic retinopathy.l56 Vitreous b-FGF levels are also raised in proliferative diabetic retinopathy and it may be that the angiogenic potential of VEGF acts synergystically with b-FGF or other angiogenic growth factors?32
Other anti-angiogenic preparations are also being tested; for example, intravitreal sustained-release TA/5FU co-drug effectively inhibits the progression of proliferative vitreal retinopathy in rabbit models that mimic human disease? 2 6 The use of various inhibitors of vascular endothelial cell growth, including somatostatin (which inhibits growth hormone), thalidomide and TGF-j3, are also under scrutiny. Because so many growth factors, cytokines and adhesion molecules act in concert to promote or contain neovascularisation, the biochemical control of vasoproliferation in diabetics is a monumental task. It also has to be remembered that many of the above-mentioned growth factors have key roles in sustaining and protecting retinal vascular cells and their manipulation may have important or as yet unseen negative effects.
The vitreous may act as a scaffold for preretinal vessels and disruption of the vitreo-retinal interface may deny neovascular fronds attachment opportunities. With this in mind Sebag 233 has developed a pharmacological vitreolysis approach using hyaluronidase digestion of the posterior vitreous cortex to induce posterior vitreous detachment at the site of new vessel growth. This may represent a novel and exciting approach to prevent neovascularisation in susceptible patients and perhaps prevent fibrotic retinal detachments.
Conclusion
The entire retina is affected in some way or other by long-standing diabetes; however, changes in the photoreceptors . and neuropile are mild, rarely threaten the survival of the cell and are generally inconsequential as far as day-to-day visual functions are concerned. The retinal microvasculature is the prime casualty of the diabetic process as its component cells experience the wear and tear of a hyperdynamic retinal circulation. These cells are also vulnerable to oxidative and glycation-related stress and become susceptible to biochemical and growth factor aberrations induced by prolonged hyperglycaemia.
Thickening of vascular basement membranes in diabetes serves to immobilise capillaries and isolate the component cells from each other and their supporting glia. This abnormal thickening may impede the normal cellular communications which moderate and influence migration, replication and continued survival of cells. Pericyte death is the key cellular event which coincides with vascular instability and eventual demise of affected capillary units. Its preferential susceptibility in diabetics is a unique and enigmatic event and may reflect pericyte sensitivity to glycation and oxidation, poor replicative capacity and possibly the ease with which this cell can be directed to apoptosis. Capillary occlusion and neovascularisation are the inescapable consequences of a failed circulation and grossly disordered metabolic events in the nearby tissues of supply.
Although the key to management of diabetic complications is optimal control of the metabolic disorder, aphysiological hyperglycaemia will always occur and prolonged overcommitment of the glycolytic and associated catabolic pathways has the potential to threaten survival of the retinal vascular cells. The recent identification and characterisation of biochemical abnormalities in vascular cells induced by hyperglycaemia has provided some hope for early therapeutic intervention. Our enhanced understanding of retinal blood flow, vasopermeability and neovascularisation also offer some prospect of treating downstream complications by the judicious modulation of growth factors and biochemical blockade of those metabolic processes which yield gratuitous and injurious end-products.
Optimisation of diabetic control, early correction of metabolic abnormalities in retinal vascular cells and a pre-emptive strike to limit or reverse vascular occlusion, impaired retinal permeability and neovascularisation are the challenges for the future and given some success it should be possible to significantly extend the functional life of the retinal circulation and guarantee a life-time of serviceable vision in most if not all diabetics. 
